Academic Unit of Oral and Maxillofacial Medicine and Pathology, Department of Clinical Dentistry, University of Sheffield, Sheffield, UK.
Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
Crit Rev Oncol Hematol. 2022 Aug;176:103745. doi: 10.1016/j.critrevonc.2022.103745. Epub 2022 Jun 20.
Adenoid cystic carcinoma (ACC) is the most common type of salivary gland cancer that can also arise in other primary sites. Regardless of the site, most ACC cases carry a recurrent chromosomal translocation - t(6;9)(q22-23;p23-24) - involving the MYB oncogene and the NFIB transcription factor. Generally, a long sequence of MYB is fused to the terminal exons of NFIB, yet the break can occur in different exons for both genes, resulting in multiple chimeric variants. The fusion status can be determined by a number of methods, each of them with particular advantages. In vitro and in vivo studies have been conducted to understand the biological consequences of MYB-NFIB translocation, and such findings could contribute to improving the current inefficient therapeutic options for disseminated ACC. This review provides a discussion on relevant evidence in the context of ACC MYB-NFIB translocations to determine the current state of knowledge and discuss future directions.
腺样囊性癌（ACC）是最常见的唾液腺癌类型，也可能发生在其他原发部位。无论发生部位如何，大多数 ACC 病例都存在反复出现的染色体易位 - t(6;9)(q22-23;p23-24) - 涉及 MYB 癌基因和 NFIB 转录因子。通常，MYB 的长序列与 NFIB 的末端外显子融合，但断裂也可能发生在两个基因的不同外显子中，导致多个嵌合变体。融合状态可以通过多种方法确定，每种方法都有其特定的优势。已经进行了体外和体内研究来了解 MYB-NFIB 易位的生物学后果，这些发现可能有助于改进目前针对广泛转移的 ACC 效率低下的治疗选择。本文综述了 ACC 中 MYB-NFIB 易位的相关证据，以确定目前的知识状态，并讨论未来的方向。
